Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide safety study in Indian patients with type 2 diabetes
NCT05659537Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2022; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05659537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659537.